CEO Of Rain Therapeutics On The Company's Developments In Cancer Treatment

Rain Therapeutics (RAIN) is a clinical-stage precision oncology company. They recently went public in 2021. Co-founder and CEO, Avanish Vellanki, speaks about Rain Therapeutics’ internal growth potential as well as the effect that its new treatment Rain-32 will have. Vellanki states that Rain-32 has been seen to triple or quadruple the survival time of patients with difficult to treat cancer. Rain Therapeutics is continuing to build a pipeline of targeted cancer therapies. Tune in to find out more.

The Watch List

01 Jun 2021

SHARE

ON AIR
education
5:30 am
Your First Trade
replay
12:00 am
Fast Market
REPLAY
1:00 am
Trading 360
REPLAY
2:00 am
Next Gen Investing
REPLAY
education
3:00 am
Your First Trade
REPLAY
3:30 am
Trading 360
REPLAY
4:30 am
Next Gen Investing
REPLAY
ON AIR
education
5:30 am
Your First Trade
REPLAY
6:00 am
Fast Market
REPLAY
7:00 am
Futures
8:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
4:00 pm
Trading 360
REPLAY
5:00 pm
Fast Market
REPLAY
6:00 pm
Next Gen Investing
REPLAY
7:00 pm
Market Overtime
REPLAY
education
7:30 pm
Your First Trade
REPLAY
8:00 pm
Trading 360
REPLAY
9:00 pm
Market Overtime
REPLAY
education
9:30 pm
Your First Trade
REPLAY
10:00 pm
Fast Market
REPLAY
11:00 pm
Trading 360
REPLAY

Get the Market Minute

Daily insights for every investor

coming soon

We are now

coming soon

We are now